|Last Price$9.33||Day Change (%)0.00%|
|Open Price$9.33||Day Change ($)0.00|
|Day Range9.33–9.33||52-Week Range9.11–9.35|
As of Fri 04/29/2016 | USD
Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients
Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Enanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
Tesla's Model X -- the luxury-loving hippie of the SUV world
Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...
Three stocks we think investors should be wary of.